ARTICLE | Company News
Canbridge gains China rights to APG101
July 16, 2015 1:19 AM UTC
Apogenix GmbH (Heidelberg, Germany) granted Canbridge Life Sciences Ltd. (Beijing, China) exclusive rights to APG101 in China, Macao and Hong Kong to treat glioblastoma multiforme (GBM), with options in additional indications.
Apogenix CEO Thomas Hoeger told BioCentury the company intends to start Phase III trials of the compound next year to treat GBM, and plans to submit regulatory applications in the U.S. and EU in 2019. Hoeger declined to disclose the development timeline in China. Canbridge did not respond to inquiries. ...